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Abstract
Background: CFS is a clinical state with defined symptoms, but undefined cause. The patients may
show a chronic state of immune activation and treatment with an antibiotic in this subgroup has
been suggested.
Methods: In a retrospective study, the response of CFS patients to azithromycin, an antibiotic and
immunomodulating drug, has been scored from the patients records and compared with clinical and
laboratory data. Azithromycin was not the first choice therapy, but offered when the effect of
counseling and L-carnitine was considered insufficient by the patient and the clinician.
Results: Of the 99 patients investigated, 58 reported a decrease in the symptoms by the use of
azithromycin. These responding patients had lower levels of plasma acetylcarnitine.
Conclusion: The efficacy of azithromycin in the responsive patients could be explained by the
modulating effect on a chronic primed state of the immune cells of the brain, or the activated
peripheral immune system. Their lower acetylcarnitine levels may reflect a decreased antioxidant
defense and/or an increased consumption of acetylcarnitine caused by oxidative stress.
Background
In 1994 Fukuda et al. [1] defined CFS as a chronic persist-
ent fatigue that is present for over 6 months, is not caused
by activity nor alleviated by rest and accompanied with at
least 4 other symptoms: cognitive impairment, pain in
joints, muscles or head, unrefreshing sleep, soar throat,
tender lymph nodes and postexertional malaise with slow
recovery. Nevertheless, CFS remained subject to debate
and even the mere existence of the syndrome was still
questioned by some. The presentation of the results of
quantitative morphology of the brain in CFS patients by
Okada et al [2], later confirmed by De Lange et al [3] may
change this opinion. The loss of grey matter in the brain,
especially in Brodmann's area 9, was related to physical
impairment, but not to the duration of the symptoms.
Although other explanations were considered as well, this
may indicate the occurrence of a major trauma to the
brain at the start of the disease. This could also explain the
low recovery rate in adults, because repair in adult brain is
limited [4].
The severity of the sickness, both the symptoms and the
lowered adaptation to physical stress, may fluctuate
whenever infections and stress come and go. The Th1 to
Th2 cytokine shift in CFS patients will make them more
vulnerable to infections [5] and it has been suggested that
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they have more often chronic infections [6-8]. The predis-
position for acquiring CFS may be genetically determined
[9,10], the occurrence is influenced by the severity of the
immune response [11]. The result is a chronic hyper-oxi-
dative state of sickness [12,13], in the brain itself [14] that
cannot be stopped [15]. Preliminary evidence of a relation
between post-infectious fatigue and mitochondrial dys-
function indicates a complex response involving acetyl-
carnitine [16].
The clinical presentation of the symptoms and chances for
recovery will depend on the balance between the irrevers-
ible loss of grey cells and activation of the immune sys-
tem. According to De Meirleir et al, the presence of RNase-
L and elastase may offer an indication for this balance [17-
19]. Several treatment protocols to counteract the
immune activation in CFS were presented [18,20,21], but
the results were never validated in a double blind study.
Such proof is required as a rationale for treatment and
provides a basis to understand the pathophysiology of the
disease. Comparing the outcome of clinical treatment
protocols might add to our knowledge of CFS and its
treatment until double blind studies are available [22].
Azithromycin is an antibiotic with immunomodulatory
effects [23-25]. This antibiotic has been successfully used
during periods of six months of more in other chronic dis-
eases [26-28]. The side-effects are known for long term use
and mainly limited to gastro-intestinal cramps. The
chances for resistance limit its use to individual patients
under close supervision [28]. The drug is relatively inex-
pensive and extensive laboratory tests for side effects are
not necessary. The result of a study in 10 CFS patients dur-
ing 1 to 2 months was positive [26]. We studied the med-
ical records of CFS patients for clinical and laboratory data
related to the outcome of the treatment with azithromy-
cin.
Methods
In the CFS and Pain Research Center Amsterdam, patients
are diagnosed with CFS according to the Fukuda criteria
[1]. Treatment protocols are discussed with the patient.
One of the treatment protocols that were offered in our
Center from April 2000 till August 2005 was azithromycin
500 mg on 3 consecutive days of the week during 6 weeks
[29]. Azithromycin was not a first choice therapy, but
offered when the effect of counseling [30] and of L-carni-
tine during more than 3 months [31] was considered
insufficient by the patient and the clinician. The period
between the L-carnitine medication and the start of azi-
thromycin was always longer than 2 weeks. The selection
was not based on symptoms or laboratory indications of
immune activity. This treatment was studied in a retro-
grade evaluation of the clinical records from April 2000 to
August 2005. The change in the clinical condition as expe-
rienced by the patient (patient rated clinical global
impression of change was scored as negative, neutral or
positive after a standard interview [32]). The change had
to be out of range of the previous fluctuations of the
symptoms for scoring as improvement or deterioration.
All patients signed an informed consent permitting the
use of the data from the clinical records for evaluation and
publication.
At the first visit all patients were evaluated according to
the protocol of the 1994 consensus meeting [1]. The
severity of CFS was determined with the Stanford Health
Assessment Questionnaire (SHAQ) [33], the Multidimen-
sional Fatigue Inventory (MFI-20) [34] and the VAS-scale
of the McGill Pain Questionnaire [35]. The presence and
severity of somatisation, distress, depression and anxiety
was scored with the 4 Dimensional Symptom Question-
naire (4DSQ) [36]. Questionnaires for disease specific
symptoms were not available at the treatment period [37].
Free carnitine and carnitine esters in plasma were ana-
lyzed using tandem mass spectrometry as described by
Vreken et al. [38].
Statistical analyses were conducted using the Statistical
Package for the Social Sciences (SPSS 14.0 for Windows,
Chicago, Ill).
Results
Of the 99 patients who were treated with azithromycin,
58 (59%) reported an improvement of symptoms. No
patients were worse at the end of the treatment. Side
effects were minor bowel problems that resolved by divid-
ing the daily dosage of azithromycin.
The majority of patients was female, 88% and 83% in the
non-responder and responder group, respectively. The
patients who reacted favorably, the responders, were
younger, 34.7 ± 11.5 years (mean ± SD) versus 40.4 ± 12.6
(Student's t-test P = 0.023, 95% CI 0.8 and 10.5), but did
not differ from the non-responders in fatigue score (MFI-
20), somatisation, distress, depression and anxiety
(4DSQ), pain score (VAS scale) or physical capacity
(SHAQ) (Table 1). Neither the history, nor the physical
examination was indicative for the response and the
standard laboratory tests did not differ between the
groups.
Plasma acetylcarnitine was lower in responders (4.78 ±
1.66 μM) compared to non-responders (5.87 ± 2.55) (P =
0.023, 95% CI 2.3 and 0.1). Plasma acetylcarnitine was
4.70 ± 1.70 μM in responding female patients (n = 48)
and 4.61 ± 1.61 μM in responding men (n = 10) (P =
0.884, 95% CI -1.2 and 0.6). These levels were in non-
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in non-responding males (n = 5) 4.88 ± 1.17 μM (P =
0.412, 95% CI -1.7 and 1.4). Because of the absence of sta-
tistical difference between the responding females and
males and also between the non-responding males and
females, we took their values together and calculated that
improvement was present in 77% of the patients with
plasma acetylcarnitine concentration less than 4.1 μM, in
58% with acetylcarnitine between 4.1 and 6.5 μM and in
31% with acetylcarnitine higher than 6.5 μM. Free and the
higher acylcarnitines were not different in responding
females and males and non-responding females and
males, and were also taken together (Table 2).
Discussion
Fifty-nine percent of the patients reported improved
symptoms of CFS after long-term use of azithromycin.
This confirms the results reported by De Becker et al. [18].
It is unlikely that this therapy is due to placebo response,
because such a response is low in CFS (19.6%) [39]. Med-
ical history, physical examination, standard laboratory
tests (data not shown) and questionnaires for the severity
of symptoms (Table 1.) did not differentiate responders
from non-responders. The reported change of symptoms
differed greatly between patients and validated test for the
severity of CFS-related symptoms was not available at that
time. Therefore we decide to present an overall impres-
sion, based on a standard interview.
The more subtle sign of metabolic (oxidative) stress was
reflected by the differences in plasma acetylcarnitine lev-
els[40].
Significant differences in plasma acetylcarnitine [41,42]
were reported in CFS, while others found no difference
[43,44]. There are several explanations for this discrep-
ancy. One explanation could be that the selection of CFS
patients differed. The patients of Kuratsune et al. [41,42]
were selected according to the CDC criteria, but Jones et al
[43] used the Oxford and CDC criteria.
The responders did not fully recover from CFS by azithro-
mycin. They improved only to an estimated maximum of
80% of the pre-morbid capacity. There are two explana-
tions for the improvement by azithromycin: A reduction
of bacterial load [26] or the immune modulating effect of
macrolides [23,45]. If CFS is caused by a primed state of
glia-cells in the brain [46] in a subgroup of patients, these
cells would produce interleukin-1β at an increased rate as
response to minor stimulation by stress or infection. The
result is a chronic and fluctuating state of sickness that is
not fully explained by the presence of an active and detect-
able disease state. Then it is likely that the immunomod-
ulating drug azithromycin could improve the severity of
CFS symptoms.
Conclusion
Lower plasma acetylcarnitine was observed in CFS
patients who responded to azithromycin. The lower
plasma acetylcarnitine level may indicate a decreased abil-
ity to counteract the action of the increased oxidative
stress and/or an increased consumption of acetylcarnitine
by the increased oxidative stress.
The response rate of 59% in this retrospective open study
is not necessarily indicative for the effect rate in prospec-
tive blinded studies.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Table 2: Mean (standard deviation) of free-carnitine and 
acylcarnitines of non-responders and responders to azithromycin 
and controls.
Plasma (acyl)carnitine Non Responders Responders P
(μmol/L) Mean (SD) Mean (SD)
Free carnitine 36.6 (9.3) 34.7 (8.3) 0.374
C2-carnitine 5.9 (2.6) 4.8 (1.7) 0.023
C3-carnitine 0.34 (0.12) 0.34 (0.15) 0.970
C4-carnitine 0.23 (0.10) 0.21 (0.11) 0.415
C8-carnitine 0.11 (0.04) 0.08 (0.04) 0.078
C14:1-carnitine 0.07 (0.04) 0.04 (0.03) 0.083
C16:1-carnitine 0.05 (0.04) 0.04 (0.02) 0.323
C18:1-carnitine 0.16 (0.10) 0.16 (0.14) 0.907
Table 1: Mean (Standard deviation) of the non-responders and 
responders to azithromycin. MFI-20: Multidimensional Fatigue 
Inventory. 4DSQ: 4 Dimensional Symptom Questionnaire. Pain 
VAS score: Visual analogue scale of the McGill Pain 
questionnaire. Stanford HAQ: Stanford Health Assessment 
Questionnaire. P: probability favoring the absence of a difference 
of the means of non-responders versus responders (Student-t 
test).
Non responders Responders P
Mean (SD) Mean (SD)
Age (y) 40.3 (12.7) 34.7 (11.5) 0.023
MFI-20: General fatigue 19.1 (1.4) 18.7 (1.8) 0.267
MFI-20: Physical fatigue 18.0 (2.3) 17.7 (2.7) 0.532
MFI-20: Mental fatigue 16.4 (3.4) 15.2 (4.2) 0.112
MFI-20: Activity 15.5 (3.3) 15.1 (3.8) 0.595
MFI-20: Motivation 11.0 (4.3) 10.1 (3.6) 0.283
4DSQ: Somatisation 0.91 (0.42) 1.11 (1.03) 0.258
4DSQ: Distress 0.89 (0.54) 0.91 (0.51) 0.859
4DSQ: Depression 0.30 (0.47) 0.35 (0.49) 0.585
4DSQ: Anxiety 0.28 (0.35) 0.33 (0.38) 0.481
Pain VAS score 27.8 (23.3) 26.8 (24.2) 0.888
Stanford HAQ 1.15 (0.19) 1.14 (0.28) 0.957Journal of Translational Medicine 2006, 4:34 http://www.translational-medicine.com/content/4/1/34
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